Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, and the mechanism of action of guselkumab.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the DDW.
The abstract ‘THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY’ was presented at Digestive Disease Week 2023, May 6-9, 2023.
- What is the burden of ulcerative colitis in patients with inadequate response to currently approved treatments? (0:14)
- What is the mechanism of action of guselkumab? (0:52)
Disclosures: Jessica Allegretti discloses consultancy for Janssen, Pfizer, Abbvie, Iterative Scopes, Finch Therapeutics, Seres Therapeutics, Ferring, Merck, Bristol Myer Squibb, Roivant and Adiso, grant/research support from Merck, Janssen and Pfizer, and Speaker’s Bureau participant with BMS, Abbvie and Janssen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of DDW 2023.
Hi, everyone. My name is Jessica Allegretti. I’m the director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital in Boston, Massachusetts.
What is the burden of ulcerative colitis in patients with inadequate response to currently approved treatments? (0:14)
So, ulcerative colitis which is one of the inflammatory bowel diseases, we know is increasing in prevalence worldwide. And we know that there are a large percentage of patients who there’s a, I would say, a big unmet need for new therapies, new mechanisms of action, because we still see many patients not responding to the current products that we have, both conventional therapies, as well as advanced therapies. And so new novel therapies are still very much needed to really increase the amount of patients that have viable options.
What is the mechanism of action of guselkumab? (0:52)
For some context, IL-23 or interleukin 23 is a proinflammatory cytokine that plays a really important role in the pathogenesis of UC, and guselkumab is a human selective IL-23 P19 subunit antagonist approved already for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis.
Subtitles and transcript are autogenerated
Share this Video
Related Videos In Inflammatory Bowel Disease
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]